Business Wire

Further Growth Sees Crestbridge Head of Institutional Client Operations Move to Luxembourg

8.7.2020 12:45:00 EEST | Business Wire | Press release

Share

Michael Newton, Head of Institutional Client Operations, will move to Luxembourg to support the growth of the Fund Services team, as the firm cements its position as a global market leader in Private Equity and Real Estate.

As Head of Institutional Client Operations, Michael is part of Crestbridge’s senior leadership team. His role has been extended so he is also responsible for growing the fund services offering from Luxembourg, where he will spend four days a week with the remaining time in Jersey, to support the firm’s growing, global fund client base. Michael will continue to oversee client facing activities within the Group’s fund, real estate and corporate services teams with a view to ensuring clients consistently receive the highest possible levels of service.

Michael’s move comes after an incredible year of growth for Crestbridge in Luxembourg, having doubled its team, made three senior hires, and moved to larger premises. This move will strengthen the firm’s client focused, multi-jurisdictional capabilities and is part of an ambitious global growth strategy.

Michael Johnson, Group Head of Institutional Services, said: “This move demonstrates the depth of talent we have to draw on from within the Crestbridge Group. Mike’s expertise, knowledge and work ethic will be invaluable as we continue to grow and support our global client base generate returns for their investors. I am delighted to have him head up our Client Operations delivery and support the growth of the Luxembourg Fund Services team and look forward to his continued contribution as a leader in the global business.”

Crestbridge already represents 90% of the top ten PERE100 and recently supported the close of one of the largest credit deals of the year, with the Bridgepoint and EQT Credit merger.

Michael continued: “Crestbridge’s longstanding presence in Luxembourg and the evolution of our service offering over the past decade initiated by Daniela Klasen-Martin generates significant value to the firm’s global capabilities. As we continue to grow, we are bolstering our business with client-focused, industry veterans. They are asset class experts who can help managers quickly close on large and complex deals, in particular within our specialisms of private equity and real estate.”

Michael Newton has over 20 years' experience in fund services, providing high-quality and efficient administration services to multi-jurisdictional fund investment structures. Since joining Crestbridge in 2017, he has helped both grow the funds business and maintain a focus on the highest levels of client service. Prior to joining Crestbridge, Michael was a Managing Director and Senior Vice President of a global fund administrator and custodian in Jersey, responsible for assets in excess of US$50bn.

Notes to editors

  • We are a leading global administration, management & corporate governance solutions business.
  • We provide a broad range of outsourced fiduciary, administrative, accounting and compliance services globally – our expertise spans services, asset classes and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers and ultra-high net worth families.
  • Crestbridge employs over 300 people and has six international offices: Bahrain, Cayman Jersey, London, Luxembourg and New York.
  • For our regulatory information please see here for more details.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Daniel Jason at Peregrine Communications
tel. +44 (0) 20 3040 0890
e-mail daniel.jason@peregrinecommunications.com

Nicola Nicholson, Head of Marketing at Crestbridge
tel. +44 (0) 1534 835014
e-mail nicola.nicholson@crestbridge.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye